Latest News
No clear evidence that adding diabetes drug to standard prostate cancer treatment reduces risk of death, but side effects of hormone therapy lessened
New results from the STAMPEDE trial metformin comparison were presented at the 2024 ESMO Congress.
Hormone patches are as effective as hormone injections for people with non-metastatic prostate cancer
New results from the PATCH and STAMPEDE trials could increase the treatment options available for people with prostate cancer who are starting long-term hormone therapy.
'25 at 25': Transforming prostate cancer treatment through the STAMPEDE clinical trial
As part of our 25th anniversary celebrations, we look at the many achievements of the STAMPEDE clinical trial, which has tested 10 different treatments and changed the standard-of-care for prostate cancer four times in less than 20 years.
People who have had post-operative radiotherapy for prostate cancer may not also need hormone therapy
Final results from the RADICALS-HD clinical trial found no evidence that the addition of hormone therapy improved how long people lived without their cancer spreading, among patients whose doctors considered them suitable for short-term, long-term or no hormone therapy.
Spotlight on our research at ESMO Congress 2024
We will present our latest prostate cancer research from the PATCH, STAMPEDE and STAMPEDE2 trials at the 2024 ESMO Congress.